Search

Your search keyword '"Fernandez-Penas, Pablo"' showing total 224 results
Start Over Author "Fernandez-Penas, Pablo"
224 results on '"Fernandez-Penas, Pablo"'

2. Trial protocol for SiroSkin: a randomised double-blind placebo-controlled trial of topical sirolimus in chemoprevention of facial squamous cell carcinomas in solid organ transplant recipients

Author

Dousset, Lea, Chambers, Daniel C., Webster, Angela, Isbel, Nicole, Campbell, Scott, Duarte, Carla, Collins, Louisa, Damian, Diona, Tseng, Anne, Karlsen, Emma, Ilinsky, Olga Victoria, Brown, Susan, Schaider, Helmut, Soyer, H. Peter, Ospino, Daniel Ariza, Hogarth, Sam, Chong, Alvin H., Mar, Victoria, McKenzie, Scott, Gin, Douglas, Fernandez-Penas, Pablo, Kern, Johannes S., Loewe, Katja, Roy, Edwige, Herschtal, Alan, and Khosrotehrani, Kiarash

Published
2024
Full Text
View/download PDF

3. Long-term cost-effectiveness of a melanoma prevention program using genomic risk information compared with standard prevention advice in Australia

Author

Newson, Ainsley J., Morton, Rachael L., Kimlin, Michael, Keogh, Louise, Law, Matthew, Kirk, Judy, Dobbinson, Suzanne J., Kanetsky, Peter, Mann, Graham, Dawkins, Hugh, Savard, Jacqueline, Dunlop, Kate, Trevena, Lyndal, Jenkins, Mark, Allen, Martin, Butow, Phyllis, Wordsworth, Sarah, Lo, Serigne, Low, Cynthia, Smit, Amelia K., Espinoza, David, Cust, Anne E., Law, Chi Kin, Fernandez-Penas, Pablo, Nieweg, Omgo E., and Menzies, Alexander M.

Published
2023
Full Text
View/download PDF

4. Study protocol for a randomised controlled trial to evaluate the use of melanoma surveillance photography to the Improve early detection of MelanomA in ultra-hiGh and high-risk patiEnts (the IMAGE trial)

Author

Yan, Mabel K., Cust, Anne E., Soyer, H. Peter, Janda, Monika, Loewe, Katja, Byars, Gabrielle, Fishburn, Paul, White, Paul, Mahumud, Rashidul Alam, Saw, Robyn P. M., Herschtal, Alan, Fernandez-Penas, Pablo, Guitera, Pascale, Morton, Rachael L., Kelly, John, Wolfe, Rory, and Mar, Victoria J.

Published
2023
Full Text
View/download PDF

7. Impact of the COVID-19 pandemic on the diagnosis and management of primary cutaneous melanomas in New South Wales, Australia: A retrospective cohort study.

Author

Thomas, Meryl, Jones-Caballero, Maria, Wijaya, Marlene, Fernandez-Penas, Pablo, and Ruiz Araujo, Raquel

Subjects
COVID-19 pandemic, COVID-19 testing, MELANOMA, DELAYED diagnosis, COHORT analysis
Abstract

Background and objective: The COVID-19 pandemic caused upheaval of healthcare systems, with evolving consequences. The aim of this study was to evaluate the impact of the pandemic on melanoma diagnosis and management in New South Wales, Australia. Methods: In this retrospective cohort study, we analysed all new melanomas diagnosed at a tertiary care hospital over a three-year period. We compared outcomes between pre-pandemic (1 January 2019 - 30 March 2020) and pandemic (31 March 2020 - 31 December 2021) periods. Results: A total of 426 melanomas were included. No significant differences in patient demographics, Breslow thickness, ulceration, subtype or lymph node positivity were observed. During the pandemic, there was an 11% decrease in the number of melanomas diagnosed in the community (P=0.016) and an 11-day reduction in time from referral to wide local excision (P=0.013). Discussion: The prioritisation of melanoma care during the pandemic in New South Wales, Australia, has resulted in no apparent diagnostic delays. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Non‐invasive diagnosis of early cutaneous squamous cell carcinoma.

Author

Azimi, Ali, Jabbour, Steven, Patrick, Ellis, and Fernandez‐Penas, Pablo

Subjects
SQUAMOUS cell carcinoma, BOWEN'S disease, MACHINE learning, EARLY diagnosis, ACTINIC keratosis, PRECANCEROUS conditions
Abstract

Early cutaneous squamous cell carcinoma (cSCC) can be challenging to diagnose using clinical criteria as it could present similar to actinic keratosis (AK) or Bowen's disease (BD), precursors of cSCC. Currently, histopathological assessment of an invasive biopsy is the gold standard for diagnosis. A non‐invasive diagnostic approach would reduce patient and health system burden. Therefore, this study used non‐invasive sampling by tape‐stripping coupled with data‐independent acquisition mass spectrometry (DIA‐MS) proteomics to profile the proteome of histopathologically diagnosed AK, BD and cSCC, as well as matched normal samples. Proteomic data were analysed to identify proteins and biological functions that are significantly different between lesions. Additionally, a support vector machine (SVM) machine learning algorithm was used to assess the usefulness of proteomic data for the early diagnosis of cSCC. A total of 696 proteins were identified across the samples studied. A machine learning model constructed using the proteomic data classified premalignant (AK + BD) and malignant (cSCC) lesions at 77.5% accuracy. Differential abundance analysis identified 144 and 21 protein groups that were significantly changed in the cSCC, and BD samples compared to the normal skin, respectively (adj. p < 0.05). Changes in pivotal carcinogenic pathways such as LXR/RXR activation, production of reactive oxygen species, and Hippo signalling were observed that may explain the progression of cSCC from premalignant lesions. In summary, this study demonstrates that DIA‐MS analysis of tape‐stripped samples can identify non‐invasive protein biomarkers with the potential to be developed into a complementary diagnostic tool for early cSCC. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry ( MelCOR ): A modified Delphi study

Author

Jobson, Dale, primary, Roffey, Benjamin, additional, Arnold, Christopher, additional, Azzi, Anthony, additional, Button‐Sloan, Alison, additional, Dawson, Tamara, additional, Fernandez‐Penas, Pablo, additional, Fishburn, Paul, additional, Gyorki, David E., additional, Hiscutt, Emma L., additional, Jakrot, Valerie, additional, Lilleyman, Alister, additional, Lochhead, Alistair, additional, Long, Georgina V., additional, Mailer, Sonia, additional, Mann, Graham, additional, McCormack, Christopher J., additional, Muir, Jim, additional, Pratt, George F., additional, Scolyer, Richard A., additional, Shackelton, Mark, additional, Shumack, Stephen, additional, Soyer, H. Peter, additional, Tan, Chin‐Guan, additional, Webb, Angela, additional, Zalcberg, John, additional, Morton, Rachael, additional, and Mar, Victoria, additional

Published
2022
Full Text
View/download PDF

39. 383 Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody: updated data from keynote 695

Author

Fernandez-Penas, Pablo, primary, Carlino, Matteo, additional, Tsai, Katy, additional, Atkinson, Victoria, additional, Shaheen, Monaster, additional, Thomas, Sajeve, additional, Mihalcioiu, Catalin, additional, Hagen, Tom Van, additional, Roberts-Thomson, Rachel, additional, Haydon, Andrew, additional, Mant, Andrew, additional, Butler, Marcus, additional, Daniels, Gregory, additional, Bunchbinder, Elizabeth, additional, Hyngstrom, John, additional, Moller, Mecker, additional, Puzanov, Igor, additional, Lance Cowey, C, additional, Whitman, Eric, additional, Ballesteros-Merino, Carmen, additional, Jensen, Shawn, additional, Fox, Bernard, additional, Schmidt, Emmett, additional, Diede, Scott, additional, Setta, Rebecca, additional, Sell, Jendy, additional, Canton, David, additional, Aung, Sandra, additional, Twitty, Christopher, additional, Xie, Sunny, additional, Lu, Ying, additional, O’Keefe, Bridget, additional, Algazi, Alain, additional, and Daud, Adil, additional

Published
2021
Full Text
View/download PDF

41. 27043 Achieving and maintaining long-term optimal improvements in patient-reported symptoms, signs, and quality of life among patients with moderate-to-severe psoriasis treated with guselkumab: 5-year data from VOYAGE 1

Author

Griffiths, Christopher E.M., primary, Blauvelt, Andrew, additional, Han, Chenglong, additional, Fernandez-Penas, Pablo, additional, Adam, David N., additional, Philipp, Sandra, additional, Song, Michael, additional, Miller, Megan, additional, You, Yin, additional, and Langley, Richard G., additional

Published
2021
Full Text
View/download PDF

43. Efficiency of Detecting New Primary Melanoma among Individuals Treated in a High-risk Clinic for Skin Surveillance

Author

Guitera, Pascale, Menzies, Scott W, Coates, Elliot, Azzi, Anthony, Fernandez-Penas, Pablo, Lilleyman, Alister, Badcock, Caro, Schmid, Helen, Watts, Caroline G, Collgros, Helena, Liu, Rose, van Kemenade, Cathelijne, Mann, Graham, Cust, Anne E, Guitera, Pascale, Menzies, Scott W, Coates, Elliot, Azzi, Anthony, Fernandez-Penas, Pablo, Lilleyman, Alister, Badcock, Caro, Schmid, Helen, Watts, Caroline G, Collgros, Helena, Liu, Rose, van Kemenade, Cathelijne, Mann, Graham, and Cust, Anne E

Abstract

Importance: A previous single-center study observed fewer excisions, lower health care costs, thinner melanomas, and better quality of life when surveillance of high-risk patients was conducted in a melanoma dermatology clinic with a structured surveillance protocol involving full-body examinations every 6 months aided by total-body photography (TBP) and sequential digital dermoscopy imaging (SDDI). Objective: To examine longer-term sustainability and expansion of the surveillance program to numerous practices, including a primary care skin cancer clinic setting. Design, Setting, and Participants: This prospective cohort study recruited 593 participants assessed from 2012 to 2018 as having very high risk of melanoma, with a median of 2.9 years of follow-up (interquartile range, 1.9-3.3 years), from 4 melanoma high-risk clinics (3 dermatology clinics and 1 primary care skin cancer clinic) in New South Wales, Australia. Data analyses were conducted from February to September 2020. Exposures: Six-month full-body examination with the aid of TBP and SDDI. For equivocal lesions, the clinician performed SDDI at 3 or 6 months. Main Outcomes and Measures: All suspect monitored or excised lesions were recorded, and pathology reports obtained. Outcomes included the incidence and characteristics of new lesions and the association of diagnostic aids with rates of new melanoma detection. Results: Among 593 participants, 340 (57.3%) were men, and the median age at baseline was 58 years (interquartile range, 47-66 years). There were 1513 lesions excised during follow-up, including 171 primary melanomas. The overall benign to malignant excision ratio, including keratinocyte carcinomas, was 0.8:1.0; the benign melanocytic to melanoma excision ratio was 2.4:1.0; and the melanoma in situ to invasive melanoma ratio was 2.2:1.0. The excision ratios were similar across the 4 centers. The risk of developing a new melanoma was 9.0% annually in the first 2 years and increased with time, part

Published
2021

44. Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition

Author

Grob, Jean-Jacques, Guminski, Alexander, Malvehy, Josep, Basset-Seguin, Nicole, Bertrand, Baptiste, Fernandez-Penas, Pablo, Kaufmann, Roland, Zalaudek, Iris, Gaudy-Marqueste, Caroline, Fargnoli, Maria Concetta, Tagliaferri, Luca, Fertil, Bernard, Del Marmol, Veronique, Stratigos, Alexander, Garbe, Claus, Peris, Ketty, Grob, Jean-Jacques, Guminski, Alexander, Malvehy, Josep, Basset-Seguin, Nicole, Bertrand, Baptiste, Fernandez-Penas, Pablo, Kaufmann, Roland, Zalaudek, Iris, Gaudy-Marqueste, Caroline, Fargnoli, Maria Concetta, Tagliaferri, Luca, Fertil, Bernard, Del Marmol, Veronique, Stratigos, Alexander, Garbe, Claus, and Peris, Ketty

Abstract

Background: No simple classification system has emerged for ‘advanced basal cell carcinomas’, and more generally for all difficult-to-treat BCCs (DTT-BCCs), due to the heterogeneity of situations, TNM inappropriateness to BCCs, and different approaches of different specialists. Objective: To generate an operational classification, using the unconscious ability of experts to simplify the great heterogeneity of the clinical situations into a few relevant groups, which drive their treatment decisions. Method: Non-supervised independent and blinded clustering of real clinical cases of DTT-BCCs was used. Fourteen international experts from different specialties independently partitioned 199 patient cases considered ‘difficult to treat’ into as many clusters they want (≤10), choosing their own criteria for partitioning. Convergences and divergences between the individual partitions were analyzed using the similarity matrix, K-mean approach, and average silhouette method. Results: There was a rather consensual clustering of cases, regardless of the specialty and nationality of the experts. Mathematical analysis showed that consensus between experts was best represented by a partition of DTT-BCCs into five clusters, easily recognized a posteriori as five clear-cut patterns of clinical situations. The concept of ‘locally advanced’ did not appear consistent between experts. Conclusion: Although convergence between experts was not granted, this experiment shows that clinicians dealing with BCCs all tend to work by a similar pattern recognition based on the overall analysis of the situation. This study thus provides the first consensual classification of DTT-BCCs. This experimental approach using mathematical analysis of independent and blinded clustering of cases by experts can probably be applied to many other situations in dermatology and oncology.

Published
2021

46. Efficiency of Detecting New Primary Melanoma Among Individuals Treated in a High-risk Clinic for Skin Surveillance

Author

Guitera, Pascale, primary, Menzies, Scott W., additional, Coates, Elliot, additional, Azzi, Anthony, additional, Fernandez-Penas, Pablo, additional, Lilleyman, Alister, additional, Badcock, Caro, additional, Schmid, Helen, additional, Watts, Caroline G., additional, Collgros, Helena, additional, Liu, Rose, additional, van Kemenade, Cathelijne, additional, Mann, Graham J., additional, and Cust, Anne E., additional

Published
2021
Full Text
View/download PDF

48. 799 Durable responses and immune activation with intratumoral electroporation of pIL-12 plus pembrolizumab in actively progressing anti-PD-1 refractory advanced melanoma: KEYNOTE 695 interim data

Author

Fernandez-Penas, Pablo, primary, Carlino, Matteo, additional, Tsai, Katy, additional, Atkinson, Victoria, additional, Shaheen, Monaster, additional, Thomas, Sajeve, additional, Mihalcioiu, Catalin, additional, Hagen, Tom Van, additional, Roberts-Thomson, Rachel, additional, Haydon, Andrew, additional, Mant, Andrew, additional, Butler, Marcus, additional, Daniels, Gregory, additional, Buchbinder, Elizabeth, additional, Hyngstrom, John, additional, Moller, Mecker, additional, Puzanov, Igor, additional, Lance Cowey, C, additional, Whitman, Eric, additional, Ballesteros-Merino, Carmen, additional, Jensen, Shawn, additional, Fox, Bernard, additional, Schmidt, Emmett, additional, Krepler, Clemens, additional, Diede, Scott, additional, Browning, Erica, additional, Hermiz, Reneta, additional, Svenson, Lauren, additional, Salazar, Jon, additional, Lee, Jack, additional, Baker, Christopher, additional, Bannavong, Donna, additional, Sell, Jendy, additional, Foerter, Kellie Malloy, additional, Canton, David, additional, Aung, Sandra, additional, Twitty, Christopher, additional, Algazi, Alain, additional, and Daud, Adil, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results